doi: 10.7501/j.issn.0253-2670.2025.14.012
Objective To reveal the mechanism of Rehmannia glutinosa iridoid glycosides (RIG) in treating type 2 diabetes mellitus (T2DM) based on network pharmacology and animal experimental verification.Methods The RIG related targets were predicted and screened by Swisstargetprediction and PharmMapper database, the target genes related to T2DM were selected using OMMI, Genecard and DisGeNET databases. The obtained common targets were imported into the STRING database to build the protein-protein interaction (PPI) network, and Cytoscape software was used to build the “drug-composition-target” and core target networks. Gene ontology (GO) function and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis were performed using the DAVID database and bioinformatics platform. T2DM mice model was established using high sugar and high-fat feeding combined with ip streptozotocin. The successfully modeled mice were randomly divided into model group, metformin (250 mg/kg) group, RIG low- and high-dose (200, 400 mg/kg) groups, with nine mice in each group, and 10 normal mice were selected as the control group. Drugs were given for intervention for eight weeks, body weight and fasting blood glucose (FBG) were measured weekly. After the last administration, serum was separated, the levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and fast insulin (FINS) were measured, the homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. The pathological changes of liver tissue in mice were observed using hematoxylin eosin (HE), Masson and oil red O staining. The expression levels of inflammatory factors interleukin-1 (IL-1), IL-6 and tumor necrosis factor-α (TNF-α) in liver tissue were measured using immunohistochemistry. Western blotting was used to detect the protein expressions of advanced glycation end products (AGEs), receptor for advanced glycation end products (RAGE), and p-p38 mitogen activated protein kinase (MAPK)/p38 MAPK levels in liver tissue. qRT-PCR was used to detect the expressions of RAGE and p38 MAPK mRNA in liver tissue.Results A total of 175 potential targets of RIG for T2DM were screened, and key core targets included proto-oncogene tyrosine-protein kinase (Src), epidermal growth factor receptor (EGFR), signal transducer and activator of transcription 3 (STAT3), etc. GO enrichment analysis showed that potential targets were mainly involved in biological processes such as the regulation of inflammatory response. KEGG pathway analysis screened 277 signal pathways, indicating that lipid and atherosclerosis, AGEs/RAGE signaling pathway and MAPK signaling pathway may play a key role in the treatment of T2DM. Animal experiment results showed that compared with model group, RIG could reduce the water intake, FBG, FINS, HOMA-IR, LDL-C levels (P < 0.01), increase HDL-C level (P < 0.01), improve liver cell morphology, alleviate liver injury, reduce collagen deposition and lipid deposition, inhibit the expressions of IL-1, IL-6, TNF-α in liver tissue (P < 0.01), and down-regulate the protein expressions of AGEs, RAGE, p-p38 MAPK/p38 MAPK and mRNA expressions of RAGE, p38 MAPK in liver tissue in T2DM mice (P < 0.05, 0.01).Conclusion RIG could effectively reduce FBG, improve insulin resistance, alleviate inflammatory response, and protect liver tissue in T2DM mice. Its mechanism may be related to the regulation of AGEs/RAGE/MAPK signaling pathway.